- Entrada Therapeutics (TRDA) is a clinical-stage biotech company focused on developing therapies for **Duchenne muscular dystrophy (DMD)** and **myotonic dystrophy type 1 (DM1)**, leveraging its proprietary **Endosomal Escape Vehicle (EEV) technology platform**.  **[1689375_2157617_0]** 
- The company reported a cash position of **$354 million**, which is projected to provide an operational runway **into Q2 2027**.  **[1689375_2157617_19]** 
- Key clinical data catalysts are anticipated in **2026**: initial patient data for the DMD exon 44 program (ENTR-601-44) in **H1 2026**, and for the DMD exon 45 program (ENTR-601-45) in **mid-2026**.  **[1689375_2157617_6]** **[1689375_2157617_19]** 
- The DM1 program (VX-670), developed in partnership with Vertex Pharmaceuticals, is expected to complete dosing and enrollment of its multiple ascending dose (MAD) portion in **2026**.  **[1689375_2157617_18]** **[1689375_2157617_19]**  Vertex initially paid **$224 million** for this preclinical asset.  **[1689375_2157617_18]** 
- Entrada's EEV platform is highlighted for its ability to achieve **high target engagement with low doses** and low manufacturing costs, offering a flexible therapeutic approach that differentiates it from competing and current therapies, particularly in the DMD landscape where gene therapies have encountered challenges.  **[1689375_2157617_4]** **[1689375_2157617_5]** **[1689375_2157617_9]** **[1689375_2157617_10]** **[1689375_2157617_16]**